Tarsus Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
TARS Nasdaq 2834 tarsusrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tarsus Pharmaceuticals, Inc.

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans - May 14th, 2026 6:30 am
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains - May 11th, 2026 10:34 pm
Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings? - May 11th, 2026 10:22 am
Tarsus to Participate in Upcoming Investor Conferences - May 7th, 2026 3:00 pm
Tarsus Pharmaceuticals Q1 Earnings Call Highlights - May 7th, 2026 12:07 am
Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 6th, 2026 6:37 pm
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates - May 6th, 2026 4:30 pm
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements - May 6th, 2026 2:05 pm
Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates - Apr 30th, 2026 3:15 pm
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 - Apr 29th, 2026 2:30 pm
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses - Apr 3rd, 2026 10:17 am
How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors - Apr 2nd, 2026 11:10 pm
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease - Mar 31st, 2026 6:30 am
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating - Mar 26th, 2026 11:04 am
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - Mar 24th, 2026 11:26 am
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - Mar 23rd, 2026 6:30 am
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? - Mar 22nd, 2026 10:28 am
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance - Mar 8th, 2026 10:12 pm
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating - Mar 6th, 2026 8:20 am
Maker Of Eye Drops Has Sights On Buy Point - Mar 2nd, 2026 11:09 am